Pharma Stability: Insights, Guidelines, and Expertise
ICH Q9 is a globally accepted guideline that provides a structured framework for identifying, assessing, and managing risks across the pharmaceutical quality system. When applied to stability testing, it helps optimize testing conditions, frequencies, and sample sizes while maintaining product safety, identity, strength, purity, and quality.
Click to read the full article.
The subject of this case study is a film-coated immediate-release tablet containing a highly stable API. The initial stability protocol included long-term storage at 25°C/60%RH, intermediate storage at 30°C/65%RH, and accelerated storage at 40°C/75%RH. Each condition had pull points at 0, 3, 6, 9, 12, 18, and 24 months, totaling over 60 data pulls per batch across three pilot-scale lots.
Click to read the full article.
Traditional stability study planning often involves default time points and storage conditions without tailored risk evaluation. As regulators expect science- and risk-driven rationales for stability protocols, stability professionals must be skilled in identifying, analyzing, and mitigating risks effectively.
Click to read the full article.
ICH Q9 emphasizes a formalized approach to identifying, analyzing, evaluating, controlling, and reviewing risks throughout the product lifecycle. Tools bridge the gap between abstract risk concepts and tangible documentation that withstands regulatory scrutiny.
Click to read the full article.
Traditional full-panel testing at every time point and condition is costly and may provide limited incremental value. Risk-based reduction offers:
Click to read the full article.
Traditional stability testing often follows a “test everything, every time” approach, which may not reflect actual product behavior or risk. Risk-based testing tailors the design and execution of studies based on factors such as:
Click to read the full article.
Not all pharmaceutical products present the same stability risks. Factors such as chemical structure, formulation, packaging, and manufacturing consistency determine degradation pathways. By evaluating these variables systematically, teams can:
Click to read the full article.
Stability protocols guide long-term product performance verification. However, a poorly designed protocol can result in:
Click to read the full article.
Agencies like USFDA and EMA expect that companies use Quality Risk Management (QRM) principles when designing stability protocols. However, such flexibility demands thorough documentation. Regulatory queries often arise due to:
Click to read the full article.
Auditors reviewing risk-based stability studies will typically focus on:
Click to read the full article.